An audit of surgical outcomes of esophageal squamous cell carcinoma

Goan, Yih-Gang; Chang, Huang-Chou; Hsu, Hon-Ki; Chou, Yi-Pin
March 2007
European Journal of Cardio-Thoracic Surgery;Mar2007, Vol. 31 Issue 3, p536
Academic Journal
Abstract: Objective: Esophageal squamous cell carcinoma and adenocarcinoma were increasingly recognized as two entities with different biologic behaviors and prognosis. Surgical risks and oncologic benefits of transthoracic and transhiatal esophagectomy for esophageal squamous cell carcinoma patients are not confessed. Methods: Between 1994 and 2005, 216 esophageal squamous cell carcinoma patients underwent esophagectomy were enrolled and analyzed retrospectively. Results: One hundred sixty-six patients underwent transthoracic esophagectomy and 50 patients underwent transhiatal esophagectomy. The overall hospital mortality and postoperative complication rates were 9.7 and 49%, respectively. The amount of intra-operative blood loss or transfusion, postoperative complication rate, lengths of hospital stay and hospital mortality rate were not significantly different between both groups. However, shorter operative time was noticed in transhiatal group (p <0.001). The overall 5-year survival rate was 16.8%. ESCC patients underwent either transthoracic or transhiatal esophagectomy had comparable long-term survival. The pTNM stage was independent prognostic factor for patients underwent transthoracic esophagectomy. However, location of tumor (p =0.009) and pathologic tumor length (p =0.012) were predictors of prognosis for patients underwent transhiatal esophagectomy. Conclusions: For esophageal squamous cell carcinoma patients, no significant differences in postoperative mortality or morbidity rates were observed between transthoracic and transhiatal esophagectomy. However, traditional pTNM staging system might underestimate the severity of esophageal squamous cell carcinoma patients who underwent transhiatal esophagectomy. The information of dissimilar prognostic factors for transhiatal or transthoracic esophagectomies will be helpful in tailoring more individualized adjuvant therapy to optimize esophageal squamous cell carcinoma patient''s outcome.


Related Articles

  • A new prognostic score for the survival of patients with esophageal squamous cell carcinoma. Nakamura, Masaki; Iwahashi, Makoto; Nakamori, Mikihito; Ojima, Toshiyasu; Katsuda, Masahiro; Iida, Takeshi; Hayata, Keiji; Kato, Tomoya; Yamaue, Hiroki // Surgery Today;May2014, Vol. 44 Issue 5, p875 

    Purpose: Recent studies have shown that the modified Glasgow Prognostic Score (mGPS), which is an inflammation-based prognostic score, is useful as a prognostic index for some cancer cases. The purpose of this study was to create a prognostic scoring system for patients with esophageal squamous...

  • Clinical study of modified Ivor-Lewis esophagectomy plus adjuvant radiotherapy for local control of stage IIA squamous cell carcinoma in the mid-thoracic esophagus. Chen, Gang; Wang, Zhou; Liu, Xiang-yan; Zhang, Ming-yue; Liu, Fan-ying // European Journal of Cardio-Thoracic Surgery;Jan2009, Vol. 35 Issue 1, p1 

    Abstract: Objective: To control the postoperative local recurrence is one of the critical factors to improve prognosis of patients with esophageal carcinoma. The aim of this study is to evaluate the effectiveness of modified Ivor-Lewis esophagectomy plus adjuvant radiotherapy for local control...

  • Primary gastric adenosquamous carcinoma in a Caucasian woman: a case report. Faria, Gil R.; Eloy, Catarina; Preto, John R.; Costa, Eduardo L.; Almeida, Teresa; Barbosa, José; Paiva, Maria Emília; Sousa-Rodrigues, Joaquim; Pimenta, Amadeu // Journal of Medical Case Reports;2010, Vol. 4 Issue 1, p1 

    Introduction: Most gastric tumors are adenocarcinomas. Primary gastric adenosquamous carcinoma is a rare malignancy, mostly associated with Asian populations. It constitutes less than one percent of all gastric carcinomas and its clinical presentation is the same as adenocarcinoma. It occurs...

  • SCC, BCC Immunotherapy. Clark, Jennifer // Dermatology Times;Jun2003, Vol. 24 Issue 6, p26 

    Examines the use of imiquimod, an immunomodulator in the treatment of invasive squamous cell carcinoma or aggressive basal cell carcinoma. Effect on immunocompromised and transplant patients; Mechanism behind the use of immunomodulators.

  • Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer. Sher, D. J.; Tishler, R. B.; Annino, D.; Punglia, R. S. // Annals of Oncology;May2010, Vol. 21 Issue 5, p1072 

    Background: Patients with node-positive head and neck squamous cell carcinomas (HNC) have a significant risk of residual disease (RD) in the neck after treatment, despite optimal chemoradiotherapy (CRT). Adjuvant neck dissection (ND) after CRT has been considered standard treatment, but its...

  • Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas.  // Journal of Translational Medicine;2011, Vol. 9 Issue 1, p139 

    The article discusses a study which addressed the impact of two single nucleotide polymorphisms (SNP) Asp299Gly and Thr399Ile of the toll-like receptor (TLR) 4 gene on the clinical outcome while accounting for the influence of adjuvant systemic therapy in a large cohort of head and neck squamous...

  • Lymph node density in oral cavity cancer: results of the International Consortium for Outcomes Research. Patel, S G; Amit, M; Yen, T C; Liao, C T; Chaturvedi, P; Agarwal, J P; Kowalski, L P; Ebrahimi, A; Clark, J R; Cernea, C R; Brandao, S J; Kreppel, M; Zöller, J; Fliss, D; Fridman, E; Bachar, G; Shpitzer, T; Bolzoni, V A; Patel, P R; Jonnalagadda, S // British Journal of Cancer;10/15/2013, Vol. 109 Issue 8, p2087 

    Background:Lymph node density (LND) has previously been reported to reliably predict recurrence risk and survival in oral cavity squamous cell carcinoma (OSCC). This multicenter international study was designed to validate the concept of LND in OSCC.Methods:The study included 4254 patients...

  • Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation). Patil, Vijay M.; Joshi, Amit; Noronha, Vanita; Sharma, Vibhor; Zanwar, Saurabh; Dhumal, Sachin; Kane, Shubhada; Pai, Prathamesh; D’Cruz, Anil; Chaturvedi, Pankaj; Bhattacharjee, Atanu; Prabhash, Kumar // International Journal of Surgical Oncology;2/3/2016, p1 

    Introduction. Sinonasal tumors are chemotherapy responsive which frequently present in advanced stages making NACT a promising option for improving resection and local control in borderline resectable and locally advanced tumours. Here we reviewed the results of 25 such cases treated with NACT....

  • Carotid sparing hypofractionated tomotherapy in early glottic cancers: Refining image guided IMRT to improve morbidity. Chatterjee, Sanjoy; Guha, Sourav; Prasath, Sriram; Mallick, Indranil; Achari, Rimpa // Journal of Cancer Research & Therapeutics;Jul-Sep2013, Vol. 9 Issue 3, p452 

    Objective: Carotid artery damage has been reported secondary to radiotherapy. We report the feasibility of implementing hypofractionated laryngeal irradiation using carotid sparing tomotherapy (HT) and analyze the image guidance (IG) policy Materials and Methods: Five patients with early glottic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics